Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Do 'chondroprotective agents' agents exist in osteoarthritis? Required proof]

M Lequesne1, C Cadet

  • 1Hôpital Léopold Bellan, Paris, France.

Therapie
|October 17, 1998
PubMed
Summary

The term "chondroprotective agent" should be replaced with "structure-modifying drug" for osteoarthritis (OA) research. Currently, no drug has demonstrated proven structure-modifying effects on OA lesions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and MRI results in 67 patients operated for gluteus medius and minimus tendon tears with a median follow-up of 4.6 years.

Orthopaedics & traumatology, surgery & research : OTSR·2014
Same author

[Systemic lupus erythematosus].

Revue medicale de France·2014
Same author

[Treatment of chronic rheumatoid polyarthritis; its history--its current status].

Revue medicale de France·2014
Same author

Descriptive epidemiology of mechanical hip pathology in adults under 50 years of age. Prospective series of 292 cases: Clinical and radiological aspects and physiopathological review.

Orthopaedics & traumatology, surgery & research : OTSR·2010
Same author

Imaging data in a prospective series of adult hip pain in under-50 year-olds.

Orthopaedics & traumatology, surgery & research : OTSR·2010
Same author

Gluteal tendinopathy in refractory greater trochanter pain syndrome: diagnostic value of two clinical tests.

Arthritis and rheumatism·2008

Area of Science:

  • Orthopedics and Rheumatology
  • Pharmacology

Context:

  • Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage and bone lesions.
  • Current terminology like 'chondroprotective agent' is insufficient to describe drugs targeting the global OA process.

Purpose:

  • To redefine the concept of drugs acting on osteoarthritis.
  • To establish criteria for identifying and evaluating structure-modifying drugs for OA.

Summary:

  • Proposes 'structure-modifying drug' as a more accurate term for agents impacting OA lesions.
  • Defines structure-modifying drugs as those preventing, retarding, stabilizing, or reversing bone and cartilage damage in OA.
  • Highlights joint-space narrowing measurement (radiochondrometry) as the current gold standard for assessing structural changes, emphasizing standardized radiographic procedures.

Impact:

  • Revises the conceptual framework for OA drug development and evaluation.
  • Emphasizes the need for robust evidence of anatomical lesion modification to confirm drug efficacy.
  • Suggests future potential for MRI in cartilage volume assessment and acknowledges limitations of chondroscopy and molecular markers.

Related Experiment Videos